ABVC BioPharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company that develops botanical-derived drugs and medical devices to address unmet medical needs in oncology/hematology, central nervous system disorders, and ophthalmology. The company offers a pipeline including ABV-1501 (Phase II for triple-negative breast cancer), ABV-1504 (Phase II completed for major depressive disorder), ABV-1505 (Phase II for adult attention deficit hyperactivity disorder), ABV-1601 (Phase I/II for depression in cancer patients), ABV-1702 (Phase II for myelodysplastic syndromes), ABV-1703 (Phase II for metastatic pancreatic cancer), ABV-1519 (Phase I/II for non-small cell lung cancer), and ABV-1701 Vitargus (Phase II medical device for retinal detachment or vitreous hemorrhage); through its subsidiary BioKey, Inc., it provides contract development and manufacturing services for nutritional and pharmaceutical products. Founded in 2015 and headquartered in Fremont, California, ABVC BioPharma conducts operations and clinical trials primarily in the United States, with collaborations and research support in Taiwan, Thailand, Australia, and partnerships involving institutions like Stanford University; it functions as a subsidiary of YuanGene Corporation and maintains co-development agreements with Rgene Corporation. Recent developments include strategic licensing partnerships in 2024-2025 with OncoX BioPharma (generating over $650,000 in milestone payments for oncology assets with potential value exceeding $41 million including equity and royalties), AiBtl BioPharma ($346,000+ in fees for psychiatric pipeline), and ForSeeCon Eye ($100,000+ for Vitargus ophthalmology indications, potentially up to $187 million); the company acquired $11 million in Taiwan facilities in 2025 to bolster manufacturing and reported $1.346 million in cumulative licensing revenue year-to-date, alongside a $3.0 million clinical services contract. These alliances and expansions support ABVC's focus on advancing plant-based therapies toward Phase III trials and commercialization, targeting global markets for herbal medicines projected to reach $347.50 billion by 2029.
Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)
ABVC BioPharma (NASDAQ:ABVC) Stock Price Down 3.4% – Time to Sell?
ABVC BioPharma (NASDAQ:ABVC) Trading Up 11.3% – Here’s Why
ABVC BioPharma (NASDAQ:ABVC) Trading Down 4.9% – Here’s What Happened
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M